Full Text View
Tabular View
Study Results
Related Studies
Reverse Shoulder Prosthesis Study (RSP)
This study has been completed.
Study NCT00764504   Information provided by Encore Medical, L.P.

First Received on September 30, 2008.   Last Updated on March 21, 2011   History of Changes
Results First Received: November 19, 2010  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Rotator Cuff Arthropathy
Failed Total Shoulder
Failed Hemi-arthroplasty
Intervention: Device: Reverse Shoulder Prosthesis

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Primary Subjects who are eligible to receive a reverse shoulder prosthesis and who have not previously received another orthopedic implant in the operative shoulder.
Revision Subjects who are eligible to receive a reverse shoulder prosthesis and who have previously received another orthopedic implant in the operative shoulder. The change in implant device is due to failure of the previously inserted orthopedic device.
Continued Access Subjects who are eligible to receive a reverse shoulder prosthesis and who have not previously received another orthopedic implant in the operative shoulder. This group are also primary subjects who were enrolled at a later date in order to collect additional data on the reverse shoulder.

Participant Flow:   Overall Study
    Primary     Revision     Continued Access  
STARTED     141     141     234  
COMPLETED     75     71     131  
NOT COMPLETED     66     70     103  
Death                 12                 6                 13  
Revision of Device                 12                 23                 14  
Physician Decision                 1                 0                 0  
Withdrawal by Subject                 1                 7                 4  
Lost to Follow-up                 40                 34                 72  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Primary Subjects who are eligible to receive a reverse shoulder prosthesis and who have not previously received another orthopedic implant in the operative shoulder.
Revision Subjects who are eligible to receive a reverse shoulder prosthesis and who have previously received another orthopedic implant in the operative shoulder. The change in implant device is due to failure of the previously inserted orthopedic device.
Continued Access Subjects who are eligible to receive a reverse shoulder prosthesis and who have not previously received another orthopedic implant in the operative shoulder. This group are also primary subjects who were enrolled at a later date in order to collect additional data on the reverse shoulder.

Baseline Measures
    Primary     Revision     Continued Access     Total  
Number of Participants  
[units: participants]
  141     141     234     516  
Age  
[units: participants]
       
<=18 years     0     0     0     0  
Between 18 and 65 years     30     52     57     139  
>=65 years     111     89     177     377  
Age  
[units: years]
Mean ± Standard Deviation
  71.9  ± 9.5     67.4  ± 11.6     71.2  ± 9.2     70.4  ± 10.1  
Gender  
[units: participants]
       
Female     87     97     136     320  
Male     54     44     98     196  
Region of Enrollment  
[units: participants]
       
United States     141     141     234     516  
Operative Shoulder  
[units: participants]
       
Right     87     83     146     316  
Left     54     58     88     200  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   American Shoulder and Elbow Surgeons Shoulder Score   [ Time Frame: 2-year ]

2.  Primary:   Average Range of Motion   [ Time Frame: 2-year ]

3.  Primary:   Subject Satisfaction With Surgery   [ Time Frame: 2-year ]

4.  Primary:   Have Surgery Again?   [ Time Frame: 2-year ]

5.  Primary:   Neer's "Limited Goals"   [ Time Frame: 2-year ]

6.  Primary:   Radiographic Failures   [ Time Frame: Post-operative, 3-month, 6-month, 1-year, 2-year ]

7.  Primary:   Safety Assessment   [ Time Frame: 2-year ]


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Manager of Clinical Affairs
Organization: DJO Surgical
phone: 512-832-9500 ext 6323
e-mail: jane.jacob@djosurgical.com


No publications provided


Responsible Party: Jane M. Jacob Ph.D., DJO Surgical
ClinicalTrials.gov Identifier: NCT00764504     History of Changes
Other Study ID Numbers: Study 300
Study First Received: September 30, 2008
Results First Received: November 19, 2010
Last Updated: March 21, 2011
Health Authority: United States: Food and Drug Administration